复星医药(02196)向专业投资者公开发行公司债券获中国证监会注册批复

Core Viewpoint - Fosun Pharma has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue technology innovation corporate bonds with a total face value of up to RMB 6 billion [1] Group 1 - The approval allows Fosun Pharma to issue the bonds to professional investors [1] - The registered application for the bond issuance is valid for 24 months from the date of approval [1] - The company can issue the technology innovation corporate bonds in multiple tranches within the validity period [1]